Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma

Completed · Phase 1

Conditions studied: Uveal Melanoma, Choroid Neoplasm

In brief

The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal melanoma who are planned to undergo enucleation or brachytherapy of the affected eye.

Key facts

Study ID

NCT02771340

Run by

Iconic Therapeutics, Inc.

People needed

10

Starts

2016-05-01

Expected to finish

2017-09-01

Last updated by the study team

2020-10-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females of any race at least 18 years of age
• Clinical diagnosis of primary uveal melanoma involving the posterior uveal tract in the study eye
• Planned enucleation or brachytherapy of the study eye due to uveal melanoma

You may not qualify if…

• Uveal melanoma in the study eye originating in the anterior uveal tract (iris)
• Hereditary or chronic hemorrhagic or coagulopathy conditions (i.e., hemophilia)
• Woman who is pregnant or lactating

Where it is running

• Study site — San Francisco, California, United States
• Study site — Denver, Colorado, United States
• Study site — Leawood, Kansas, United States
• Study site — Boston, Massachusetts, United States
• Study site — Grand Rapids, Michigan, United States
• Study site — Royal Oak, Michigan, United States
• Study site — Portland, Oregon, United States
• Study site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.